Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions
Immuno · 05.07.2024 · 4 (3) · 186-210
DOI: 10.3390/immuno4030013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immuno, online erschienen am 05.07.2024. Verfasst von Abdullah Younis und 1 weiteren Autor:innen. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICI) are a promising form of immunotherapy that have significantly changed the therapeutic landscape for many advanced cancers. They have shown unique clinical benefit against a broad range of tumour types and a strong overall impact on survival in studied patient populations. However, there are still many limitations holding back this immunotherapy from reaching its full potential as a possible curative option for advanced cancer patients. A great deal of research is being undertaken in the hope of driving advancements in this area, building a better understanding of the mechanisms behind immune checkpoint inhibition and ultimately developing more effective, safer, and wider-reaching agents. Taking into account the current literature on this topic, this review aims to explore in depth the basis of the use of ICIs in the treatment of advanced cancers, evaluate its efficacy and safety, consider its current limitations, and finally reflect on what the future holds for this very promising form of cancer immunotherapy.
Zitieren
APA
Younis, A., & Gribben, J. (2024). Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions. Immuno, 4(3), 186-210. https://doi.org/10.3390/immuno4030013
Vancouver
Younis A, Gribben J. Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions. Immuno. 2024;4(3):186-210. doi:10.3390/immuno4030013
BibTeX
@article{Younis2024,
author = {Younis, Abdullah and Gribben, John},
title = {Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions},
journal = {Immuno},
year = {2024},
volume = {4},
number = {3},
pages = {186--210},
doi = {10.3390/immuno4030013}
}
EUVIMED